Cell Therapy Shows Remarkable Ability to Eradicate Cancer in Clinical Study

Friday, February 21, 2014

An immunotherapy advance pioneered at Memorial Sloan Kettering continues to demonstrate remarkable results. Researchers reported in Science Translational Medicine that 88 percent of advanced leukemia patients achieved complete remissions after being treated with genetically modified versions of their own immune cells.

The new treatment, known as targeted immunotherapy, harnesses the power of the body’s own immune system to fight cancer. Patients’ own immune cells, called T cells, are removed and genetically altered to recognize and attack a protein found on cancer cells. They are then infused back into the patient, where they multiply and attack.

Study authors Renier Brentjens and Michel Sadelain are available to discuss the current research findings and the implications for future study. Patients who have received novel immune therapies are also available for interviews.

Add new comment

We welcome your questions and comments. While we share many of them with our world-class doctors and researchers, we regret that in order to protect your privacy, we are not able to make personal medical recommendations on this forum, nor do we publish comments that contain your personal information. If you would like to consult with an MSK doctor, we encourage you to make an appointment at 800-525-2225 or request an appointment online.

Your email address is kept private and will not be shown publicly.